[Treatment of malignant melanomas. Trial of D.T.I.C. by intra-arterial infusion].
D.T.I.C. appears more and more to possess the characteristics of an effective chemical agent in the treatment of naevocarcinoma. Having been able to include it in a mixed chemotherapy programme used in a group of 44 patients, we report here our findings. This is a preliminary study, the results of which will have to be confirmed in time on a larger group of patients over a longer period of observation.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014226:Triazenes / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D014226:Triazenes; D003606:Dacarbazine
Traitment des mélanomes malins. Essai d'utilisation du D.T.I.C. en infusion intra-artérielle